Edgewise Therapeutics Faces Stock Volatility Amid Analyst Optimism Edgewise Therapeutics' stock has experienced recent declines, trading down 3.5% on Wednesday to $25.61. Despite the dip, analysts remain optimistic, with price targets reaching up to $56. The company’s pipeline, including late-stage trials for sevasemten and EDG-7500, is seen as a key driver for potential growth.123